Mr. Dvořáček, in 2010, the AIFP commissioned a study on the economic footprint of the innovative pharmaceutical industry in the Czech Republic. Can you begin by…
In Conversation
Mr. Kotek, can you please begin by introducing us to the SVOPL and telling us what the mission is here in the Czech Republic? We are…
The group has significantly invested in Poland. Are you today generally satisfied with the initial and follow up investments from Mediq in the country? The group…
As a partner at Apposite since the company was created in 2006, what was the founding vision of the company and what do you consider have…
Apitope’s research and success is based on its High Speed Technology Platform that uses soluble peptides as vehicles to regulate immune responses in patients. What is…
Agendia has experienced remarkable growth in the seven years since you founded the company. In 2009 you expanded the company’s Amsterdam facilities and, in 2010, you…
Founded in 1997 Actelion is certainly the “new kid on the block” when compared to some of the much older mainstays in the pharmaceutical industry. What…
If you could provide our readers with your philosophy when you founded Sayenko Kharenko in 2004. What were the market needs that were perhaps missing that…
It has been one year since you were appointed as the head of UCB’s operations in Ukraine. What was the mission of your assignment when you…
Considering you only took over as CEO from your father in 2009, what was the mandate that was given to you as new CEO of the…
Orion’s global strategy focuses on the CIS and Eastern European markets that still exhibit large growth potential and are expanding, despite a reverse trend for the…
What were the factors that led to Sanofi’s decision to establish an LLC in 2009 in Ukraine, and how has it changed your operations? Most of…
